arrow
A

Anna V. Kovyrshina

gamalei federal research centre for epidemiology and microbiology
H指数:10
被引数:3,326

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sputnik V update: safety and neutralizing antibodies in healthy adults and adolescents

卫星V疫苗更新:健康成人和青少年中的安全性与中和抗体

2026-03-270
OA
An Ex Vivo Lung Histoculture Model for Studying Pulmonary Infection and Immune Response With SARS-CoV-2 as an Example of RNA Virus

一种用于研究肺感染和免疫反应的离体肺组织培养模型——以SARS-CoV-2为例说明RNA病毒

2025-12-200
PRE
Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus Challenge

表达优化后WNV preM/E基因的腺病毒载体可提供对致死性西尼罗病毒攻击的长期保护

2025-11-210
OAAI
Immunization route-mediated differences in long-term maturation of humoral immune response induced by adenovirus vector-based COVID-19 vaccine Sputnik V in nonhuman primates

腺病毒载体COVID-19疫苗Sputnik V在非人灵长类动物中诱导的体液免疫反应长期成熟过程中,免疫途径介导的差异

2025-09-190
OAAI
Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia

GamEvac-Combi,一种异源rVSV-和rAd5载体埃博拉疫苗的安全性与免疫原性:一项在几内亚共和国和俄罗斯进行的随机对照多中心临床试验

2025-03-200
OA
Cytokine production in an ex vivo model of SARS-CoV-2 lung infection
2024-10-210
OAAI
Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5

Sputnik V疫苗在hACE2-Transgenic小鼠中针对同源和异源SARS-CoV-2谱系 (包括远距离Omicron BA.5) 的免疫原性和保护性

2024-10-080
OAAI
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
2023-10-201
OAAI
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

基于rAd26和rAd5载体的异源初免-加强新型冠状病毒肺炎疫苗对健康青少年SARS-CoV-2的安全性和免疫原性: 一项开放标签、非随机、多中心、1/2期、剂量递增研究

2023-08-014
OAAI
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
2023-03-306
OAAI
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

鼻内递送的基于载体的异源启动-加强新型冠状病毒肺炎疫苗Sputnik V在小鼠和非人灵长类动物中的免疫原性和保护性

2022-09-2610
OAAI
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

在Sputnik V疫苗接种的个体中保留针对SARS-CoV-2 Omicron变体的中和反应

2022-05-2120
OAAI
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern

单域抗体可有效中和SARS-CoV-2相关变异

2022-02-2419
OAAI
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults
2021-12-0142
OAAI
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Sputnik V疫苗接种人群的血清对关注变体 (VOC: B.1.1.7,B.1.351,P.1,B.1.617.2,B.1.617.3) 和莫斯科地方性SARS-CoV-2变体的中和活性

2021-07-1288
OAAI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

基于rAd26和rAd5载体的异源启动-加强新型冠状病毒肺炎疫苗的安全性和有效性: 俄罗斯一项随机对照3期试验的中期分析

LANCET
IF88.5
2021-02-011.2K
OAAI
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

两种制剂中基于rAd26和rAd5载体的异源启动-加强新型冠状病毒肺炎疫苗的安全性和免疫原性: 来自俄罗斯的两项开放,非随机1/2期研究

LANCET
IF88.5
2020-09-01732
OAAI